MUMBAI: Shares of Suven Life Sciences touched a 52-week high after the firm said it was in talks with four global pharmaceutical firms, which
have shown an interest in outlicense deals for SUVN-502, its lead drug candidate for Alzheimer's disease.

However, the size of deal would be known only af..